SCHEMBL4229277

SCHEMBL4229277

CN1C(=O)OCC1Cc1ccc(Oc2ccc([N+](=O)[O-])cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.43
KCNJ1 P48048 2/20 0.43
KCNH2 Q12809 2/20 0.43
LTA4H P09960 1/20 0.43
PTGS1 P23219 1/20 0.43
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 3/20 0.40
HSPB1 P04792 1/20 0.40
CYP3A4 P08684 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
HSD17B10 Q99714 1/20 0.40
HTT P42858 1/20 0.40
RECQL P46063 1/20 0.40
PGR P06401 1/20 0.40
HTR1D P28221 1/20 0.39
HTR1B P28222 1/20 0.39
MMP1 P03956 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13757293 1.00 PTGS2 (0.43) PTGS2KCNJ1KCNH2LTA4HPTGS1
SCHEMBL7811642 0.93 KMT2A (0.46) KCNJ1KCNH2KMT2ASMN1; SMN2ALDH1A1
SCHEMBL7811646 0.93 KMT2A (0.46) KCNJ1KCNH2KMT2ASMN1; SMN2ALDH1A1
SCHEMBL4507577 0.84 RAB9A (0.52) KMT2ASMN1; SMN2MEN1ALDH1A1POLB
SCHEMBL4517058 0.84 PKM (0.36) PTGS2KCNJ1KCNH2LTA4HPTGS1
SCHEMBL5337499 0.84 PKM (0.36) PTGS2KCNJ1KCNH2LTA4HPTGS1
SCHEMBL4516666 0.83 HTR1D (0.41) PTGS2LTA4HPTGS1SMN1; SMN2ALDH1A1
SCHEMBL13757292 0.83 HTR1D (0.41) PTGS2LTA4HPTGS1SMN1; SMN2ALDH1A1
SCHEMBL5339982 0.82 GAA (0.35) PTGS2KCNH2LTA4HPTGS1KMT2A
SCHEMBL4505020 0.82 GAA (0.35) PTGS2KCNH2LTA4HPTGS1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203744-A1 NOVEL PYRIDINE DERIVATIVES ORCHID RESEARCH LABORATORIES LIMITED (IN) 2009-08-13 US disclosed
US-20090131420-A1 Novel Heterocyclic Analogs of Biphenyl Ethers ORCHID RESEARCH LABORATORIES, LTD. (IN) 2009-05-21 US disclosed
WO-2007042878-A1 NOVEL HETEROCYCLIC ANALOGS OF BIPHENYL ETHERS ORCHID RESEARCH LABORATORIES LIMITED (IN) 2007-04-19 WO disclosed
WO-2007029062-A2 NOVEL PYRIDINE DERIVATIVES ORCHID RESEARCH LABORATORIES LIMITED (IN) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203744-A1 NOVEL PYRIDINE DERIVATIVES CYP3A4, CYP4B1, CYP3A5 PTGS2 1014/4885KCNJ1 496/4885KCNH2 863/4885
US-20090131420-A1 Novel Heterocyclic Analogs of Biphenyl Ethers UGT2B7, CYP4B1, CYP1B1 PTGS2 2888/4885KCNJ1 1034/4885KCNH2 1254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.